Dextrose, unspecified form

Dextrose Injection (5% and 10%) is indicated as a source of water and calories in adult and pediatric patients, and may also be used as a diluent for reconstitution of a powder or liquid drug product.

Dextrose provides a source of carbohydrate calories and is used to supplement nutrition by providing glucose parenterally.

Only for intravenous infusion. Infusion rate depends on the age, weight, clinical and metabolic conditions of the patient and concomitant therapy. See full prescribing information for more information on preparation, administration, and dosing considerations.

Dextrose Injection (5% and 10%) is contraindicated in patients with: Clinically significant hyperglycemia. Known hypersensitivity to dextrose. Clinically significant hyperglycemia.

Neonatal Hypoglycemia: Closely monitor blood glucose concentrations to ensure adequate glycemic control. Hyperglycemia and Hyperosmolar Hyperglycemic State: Use with caution in patients with known subclinical or overt diabetes mellitus. Hypersensitivity Reactions: Monitor for signs and symptoms and discontinue infusion immediately if reaction occurs. Phlebitis and Thrombosis: Remove catheter as soon as possible if thrombophlebitis develops. Hyponatremia: Monitor serum sodium and chloride concentrations, fluid status, acid-base balance, and neurologic status. Electrolyte Imbalance and Fluid Overload: Monitor changes in fluid balance, electrolyte concentrations, and acid-base balance during administration. Refeeding Syndrome: Monitor laboratory parameters.

The following clinically significant adverse reactions are described elsewhere in the labeling: Neonatal Hypoglycemia Hyperglycemia and Hyperosmolar Hyperglycemic State Hypersensitivity Reactions Phlebitis and Thrombosis Hyponatremia Electrolyte Imbalance and Fluid Overload Refeeding syndrome The following adverse reactions associated with the use of Dextrose Injection (5% and 10%) were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Administration site conditions: Blister, erythema, extravasation, pain, phlebitis, vein damage, thrombosis. Immune system disorders: Anaphylaxis, angioedema, bronchospasm, chills, hypotension, pruritus, pyrexia, rash.

Effects on Glycemic Control and Electrolyte Balance: Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations, and acid-base balance. Avoid use of Dextrose Injection in patients receiving drugs associated with hyponatremia.

Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to 30°C (59°F to 86°F). Protect from freezing.